Clearside Biomedical announces enrollment, dosing of participants in ODYSSEY

Clearside Biomedical, announced that the enrollment and dosing of participants is underway in ODYSSEY, its randomized, Phase 2b clinical trial of CLS-AX in neovascular age-related macular degeneration. “The ODYSSEY clinical trial is off to a solid start with the activation of multiple U.S. based clinical sites,” said George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer. “Multiple participants have been enrolled and we have initiated the randomization of participants to receive either CLS-AX or aflibercept one month after they received the first loading dose of aflibercept. This study builds upon the promising data from our OASIS trial in which 67% of extension study participants in Cohorts 3 and 4 went at least 6 months without additional treatment. CLS-AX has the potential to be a twice-a-year treatment for wet AMD, which could reduce the onerous treatment burden for patients who currently require more frequent dosing and numerous office visits with existing approved drugs. We expect to report topline data in the third quarter of 2024,” concluded Dr. Lasezkay.